SEI增強型低波動性美國大型股主動型ETF SELV 深 滬
已收盤 07-02 16:00:00 美东时间
33.43
+0.490
+1.49%
華盛通- 最 高33.43
- 今 開33.19
- 成交量 1.09万股
- 最 低 33.16
- 昨 收 32.94
- 總市值 2.42亿
- 52周最高 33.8283
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 30.003
- 委 比 0.00%
- 總股本 725.11万
- 歷史最高 33.8283
- 量 比 0.20
- 振 幅 0.82%
- 歷史最低 20.2766
- 每 手 1
- 風險率 0.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Palvella completes FDA pre-NDA meeting for QTORIN rapamycin gel in microcystic lymphatic malformations
Palvella completes FDA pre-NDA meeting for QTORIN rapamycin gel in microcystic lymphatic malformations Palvella Therapeutics completed an FDA pre-NDA meeting for QTORIN rapamycin gel in microcystic lymphatic malformations. Phase 3 SELVA results were already generated and reviewed with FDA, including
06-03 19:31
Palvella Therapeutics Presents New Clinical Data From Phase 3 SELVA And Phase 2 TOIVA Studies At ISSVA World Congress 2026
In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as "Much Improved" (+2) or "Very Much Improved" (+3) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA)
05-21 04:35
Palvella Therapeutics To Highlight Results From Phase 3 SELVA And Phase 2 TOIVA Studies Of QTORIN Rapamycin At ISSVA World Congress 2026
James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ETWAYNE, Pa., April 20, 2026 (GLOBE
04-20 19:32
Palvella Therapeutics announces Phase 2 DSAP trial start in H2 2026; Phase 3 SELVA study meets primary endpoint on mLM-IGA (p<0.001)
Palvella Therapeutics announces Phase 2 DSAP trial start in H2 2026; Phase 3 SELVA study meets primary endpoint on mLM-IGA (p<0.001) Palvella reported that it will present two posters at the 2026 American Academy of Dermatology Annual Meeting, including data on QTORIN rapamycin topical formulation w
03-27 22:30
Palvella surges on late-stage trial win for lead asset
Shares of Palvella Therapeutics (PVLA) rose more than 30% on Tuesday after the company announced that a late-stage trial for its lead asset, Qtorin rapamycin, reached its main goals, paving the way fo...
02-25 00:27
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
02-24 23:07
Dow Gains Over 100 Points; Home Depot Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more th...
02-24 22:50
Palvella Reports Positive Phase 3 Data for QTORIN Gel
The latest update is out from Palvella Therapeutics ( ($PVLA) ). On February 24...
02-24 21:17
Palvella Therapeutics to Host Call on Phase 3 SELVA Topline Results for QTORIN Rapamycin Gel in Microcystic Lymphatic Malformations
Palvella Therapeutics to Host Call on Phase 3 SELVA Topline Results for QTORIN Rapamycin Gel in Microcystic Lymphatic Malformations Palvella Therapeutics Inc. announced it will host a conference call and webcast on Feb. 24, 2026, to discuss topline results from the Phase 3 SELVA clinical trial evalu
02-24 06:00
Palvella Therapeutics to Host Conference Call and Webcast on Phase 3 SELVA Topline Results for QTORIN Rapamycin in Microcystic Lymphatic Malformations
Palvella Therapeutics to Host Conference Call and Webcast on Phase 3 SELVA Topline Results for QTORIN Rapamycin in Microcystic Lymphatic Malformations Palvella Therapeutics Inc. will host a conference call and webcast on Tuesday, February 24, 2026 at 8:00am ET to discuss topline results from the Pha
02-24 06:00
